Editas Medicine
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 265
- Market Cap
- $315M
- Introduction
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
- Conditions
- HemoglobinopathiesSickle Cell DiseaseTransfusion-dependent Beta-Thalassemia
- Interventions
- Other: Safety and efficacy assessments
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Editas Medicine, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT06363760
- Locations
- 🇺🇸
Smilow Cancer Hospital, New Haven, Connecticut, United States
🇺🇸Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States
🇺🇸Children's Healthcare of Atlanta, Atlanta, Georgia, United States
EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)
- Conditions
- HemoglobinopathiesTransfusion Dependent Beta ThalassemiaThalassemia IntermediaThalassemia Major
- Interventions
- Genetic: EDIT-301
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Editas Medicine, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05444894
- Locations
- 🇺🇸
University of California San Francisco, Oakland, California, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)
- Conditions
- HemoglobinopathiesSickle Cell Disease
- Interventions
- Genetic: EDIT-301
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Editas Medicine, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT04853576
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital, Oakland, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Smilow Cancer Hospital, New Haven, Connecticut, United States
Single Ascending Dose Study in Participants With LCA10
- Conditions
- Leber Congenital Amaurosis 10Inherited Retinal DystrophiesEye Diseases, HereditaryRetinal DiseaseVision DisordersRetinal DegenerationEye Disorders Congenital
- Interventions
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Editas Medicine, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT03872479
- Locations
- 🇺🇸
Bascom Palmer Eye Institute, Miami, Florida, United States
🇺🇸Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
🇺🇸W.K. Kellogg Eye Center - University of Michigan, Ann Arbor, Michigan, United States
Natural History Study of CEP290-Related Retinal Degeneration
- Conditions
- Vision DisordersEye Diseases, HereditaryRetinal DiseaseLeber Congenital Amaurosis 10Eye DiseasesRetinal DegenerationBlindnessEye Disorders Congenital
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Editas Medicine, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT03396042
- Locations
- 🇺🇸
Casey Eye Institute - OHSU, Portland, Oregon, United States
🇫🇷Universite Pierre et Marie Curie, Paris, France
🇺🇸W.K. Kellogg Eye Center, Ann Arbor, Michigan, United States